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Background: Hazelnut allergy, which is characterized by symptoms that range from 
mild to severe, is one of the most common allergies in children throughout Europe, 
and an accurate diagnosis of this allergy is therefore essential. However, lipophilic 
allergens, such as oleosins, are generally underrepresented in diagnostic tests. We 
therefore sought to characterize the IgE reactivity of raw and roasted hazelnut oleo-
sins, using the sera of hazelnut- allergic pediatric patients.
Methods: Raw and roasted hazelnut oil body– associated proteins were analyzed by 
means of 1D and 2D electrophoresis and MS. Oleosin IgE reactivity was assessed 
by immunoblotting with the sera of 27 children who have confirmed hazelnut aller-
gies and from 10 tolerant subjects. A molecular characterization of the oleosins was 
performed by interrogating the C. avellana cv. Jefferson and cv. TGL genomes, and 
through expression and purification of the recombinant new allergen.
Results: A proteomic and genomic investigation allowed two new oleosins to be 
identified, in addition to Cor a 12 and Cor a 13, in hazelnut oil bodies. One of the 
new oleosins was registered as a new allergen, according to the WHO/IUIS Allergen 
Nomenclature Subcommittee criteria, and termed Cor a 15. Cor a 15 was the most 
frequently immunorecognized oleosin in our cohort. Oleosins resulted to be the 
only immunorecognized allergens in a subgroup of allergic patients who showed low 
ImmunoCAP assay IgE values and positive OFC and PbP. Hazelnut roasting resulted in 
an increase in oleosin immunoreactivity.
Conclusion: A novel hazelnut oleosin, named Cor a 15, has been discovered. Cor a 
15 could play a role in eliciting an allergic reaction in a subgroup of pediatric patients 
that exclusively immunorecognize oleosins. The high prevalence of hazelnut oleosin 
sensitization here reported further confirms the need to include oleosins in routine 
diagnostic procedures.
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1  |  INTRODUC TION
Hazelnut (Corylus avellana L.) allergy is the most common tree nut al-
lergy in Europe1, with a different prevalence being observed among 
European countries.2 Associated oil body (OB) proteins have been 
receiving increasing interest, since oleosins have been described as 
major allergens in peanuts3,4 and in sesame.5,6 Moreover, they have 
been associated with severe symptoms as a result of the consump-
tion of hazelnuts.7,8 In 2015, the EuroPrevall project2 established 
that hazelnut oleosin sensitization is quite common in Europe (which 
has from 10 to 25% of hazelnut- allergic patients), with a higher prev-
alence in children than in adults (34% vs 11.4%). Akkerdaas et al.9 
reported the two first allergenic oleosins in hazelnuts, Cor a 12 and 
Cor a 13.
Oleosins are usually underrepresented in skin prick test (SPT) ex-
tracts and in vitro reagents, thereby giving rise to false negatives in 
hazelnut allergy diagnosis.7,10 Their absence in test reagents is due 
to their hydrophobic structure, which results in their eluding the 
standard protein purification procedures. Zuidmeer- Jongejan et al.7 
pointed out the absence of Cor a 12 and Cor a 13 in nine of the most 
commonly used SPT extracts.
The IgE binding potential of peanut oleosins has recently been 
found to be increased by in- shell roasting.4 However, the effect of 
roasting on hazelnut oleosin immunorecognition remains unknown.
Our aim was to investigate the contribution of oleosins to hazel-
nut pediatric allergies and to assess the effect of roasting on hazel-
nut oleosin immunogenicity.
2  |  METHODS
Details about the methods used for most of the conducted experi-
ments are available in the Online Repository.
2.1  |  Study population and clinical methods
Pediatric subjects with a convincing history of hazelnut allergy (HA 
patients, no. = 27) and pediatric subjects sensitized but tolerant 
to hazelnuts (HS patients, no. = 10) were retrospectively recruited 
from the Paediatric Allergy Unit, Regina Margherita Children’s 
Hospital (Città della Salute e della Scienza, Turin, Italy). Hazelnut 
allergy was defined as a convincing history of allergic symptoms 
(oral allergy syndrome (OAS), urticaria, angioedema, respiratory, 
cardiovascular, and/or gastrointestinal symptoms) appearing within 
1 h after hazelnut ingestion. The allergy diagnosis was confirmed 
by means of an oral food challenge (OFC) (except for patients 
with severe anaphylaxis), by prick by prick (PbP), and by hazelnut 
sIgE dosed with ImmunoCAP (Thermo Fisher Scientific, Uppsala, 
Sweden) (Table 1).
All the HA patients reported having had a reaction to foods con-
taining roasted hazelnuts (cocoa, hazelnut spreads, chocolate, ha-
zelnut ice cream, chocolate pralines with whole roasted hazelnuts, 
or hazelnut nougat). For this reason, the OFC was performed with 
finely ground roasted hazelnuts.
The OFC was initiated using one drop of physiological solution 
mixed with the hazelnut powder and placing the solution on the 
inner side of the lower lip. The challenge was continued with in-
creasing doses of hazelnut powder (0.2 g, 0.4 g, 1 g, 2 g, 3 g, 6 g, 
8 g, and 10 g) administered in 20- min intervals, unless symptoms 
occurred or until a total cumulative dose of 30 g of hazelnut pow-
der (equivalent to 15 hazelnuts). The OFC procedure was stopped 
after observation of the first objective symptom. In the case of mild 
objective or subjective symptoms, it was decided to wait longer 
for the subsequent dose and/or to repeat the same dose, and the 
OFC procedure was stopped in the case of persistent symptoms 
(lasting longer than 30 minutes) and/or worsening symptoms and 
in the case of repeated elicitation (over 3 doses). The scoring of the 
severity of the reaction to the OFC was evaluated independently by 
two allergy specialists (G.M. and R.C.), and the results were coded 
as mild, moderate, or severe, according to the Integrated Grading 
System for Scoring Reaction Severity of Oral Food Challenge 
Reactions of Zhu et al.11
All the patients underwent PbP, using both raw and roasted ha-
zelnuts. Histamine (10 mg/ml) was used as a positive control, and a 
saline solution was used as the negative control. PbP was considered 
positive if the wheal was higher than 3 mm, and there was no reac-
tion to the negative control.
The IgEs sera were assayed against a hazelnut extract, rCor a 1, 
rCor a 8, rCor a 9, rCor a 14, and rBet v 1 using ImmunoCAP. The cut-
off for positivity was set at 0.10 KU/l. rCor a 1, rCor a 8, rCor a 9, and 
rCor a 14 sIgE concentrations were standardized for the statistical 
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analysis by subtracting the mean values of each variable and then 
dividing by the corresponding standard deviations. The sIgE values 
below the limit of detection (<0.10 KU/L) were assigned a value of 
0.01; the sIgE values above the limit of detection (>100 KU/L) were 
assigned a value of 100. Missing data (codified in Table 1 with n.d.) 
were not considered in the statistical analysis. The standardized data 
of the patients classified as HA versus the patients classified as HS 
were analyzed by means of nonparametric Kruskal- Wallis one- way 
ANOVA, because of the non- normal distribution. The correlation 
between the standardized sIgE concentrations of the different aller-
gens was calculated by means of Kendall’s tau. All the analyses were 
performed using PAST software, version 2.17.12
A subgroup of the HA patients (patient nos. 23, 24, 25, 26, and 
27), who were characterized by low rCor a 1, rCor a 8, rCor a 9, 
and rCor a 14 ImmunoCAP IgE values, ranging from 0.10 kU/L to 
1.88 kU/L, were defined as low ImmunoCAP hazelnut- allergic (LIHA) 
patients.
The HS patients were characterized according to the presence 
of atopic dermatitis (AD) and/or other food allergy (FA) and/or other 
nut allergies (NA), with a positive PbP to hazelnut and/or positive 
sIgE to hazelnut, but negative to OFC.
The experimental controls were the sera of non- nut- allergic pe-
diatric subjects (NNA) and of non- food- allergic pediatric subjects 
(NFA), used individually or pooled.
The study was approved by the local ethics committee of the 
Città della Salute e della Scienza (Turin, Italy) (approval no. 312, prot. 
no. 22050). The parents of all the patients gave written informed 
consent.
2.2  |  Hazelnut water- soluble and OB- associated 
protein extraction
Raw hazelnuts (Corylus avellana cv. Tonda Gentile delle Langhe, TGL) 
were obtained from experimental fields, roasted at a laboratory scale 
(120°C for 30 min), and used for the OFC, PbP, and immunoblotting 
experiments. The water- soluble proteins were extracted according 
to Platteau et al.13 The hazelnut OBs were isolated according to Cao 
et al.14 and the OB- associated proteins were extracted according to 
Lamberti et al., 2020.15
2.3  |  Protein separation by means of LDS- 
PAGE, 2- dimensional electrophoresis (2- DE), and 
immunoblotting analysis
The hazelnut water- soluble proteins were separated by means 
of LDS- PAGE. The OB- associated proteins were separated by 
means of both LDS- PAGE and 2- DE. Protein bands and spots were 
electro- transferred to PVDF membranes and incubated with the 
patient’s serum. Immunoblotting was developed using an Alkaline 
Phosphatase Substrate Kit (Bio- Rad).
2.4  |  Use of sera
Individual serum was used for 1D immunoblotting of the OB protein 
extracts, ELISA, and an immunoblotting inhibition assay with a raw 
OB protein extract. Pooled sera were used for the remaining experi-
ments: 2D immunoblotting of the OB protein extracts, an immuno-
blotting inhibition assay with rCor a 15, and immunoblotting of the 
total water- soluble hazelnut protein extracts, due to the paucity of 
the available sera.
2.5  |  Protein identification by means of MALDI- 
TOF/TOF and ESI- Q- TOF analyses
In- gel digestion was performed to identify the allergens contained 
in the bands and spots from the gel electrophoresis, as in Nebbia 
et al.,16 and protein identification was performed by coupling the 
MALDI- TOF/TOF17 and ESI- Q- TOF- MS techniques.15 The spectra 
were searched against the NCBI C. avellana database implemented 
with two new oleosin sequences derived from both the C. avellana 
cv Jefferson genome18 and C. avellana cv TGL.19
2.6  |  Expression and purification of recombinant 
Cor a 15
In order to establish whether the newly discovered oleosin was an 
allergen, it was produced as a recombinant protein. Its complete 
coding sequence, obtained by means of RNA retrotranscription, was 
cloned in a pGEM- T Easy vector (Promega, Madison, WI, The USA) 
and sent to PRIMM (Milan, Italy) for protein expression and purifica-
tion. The full- length allergen (rCor a 15) and the C- terminal fragment 
(rCor a 15 C- term, from aa 102 to aa 169) were used for the blot inhi-
bition studies, and only the full- length rCor a 15 was used for ELISA.
2.7  |  Quantification of Cor a 15- specific IgEs by 
means of direct ELISA test
IgEs specific to rCor a 15 were quantified as described in Hilger 
et al.,20 with some modifications. Briefly, patient sera (10 HA, 3 
LIHA, 2 HS, 9 NNA, and 9 NFA patients) were transferred to 96- well 
plates previously coated with 0.1 µg/ml of rCor a 15. In order to 
obtain a semi- quantification of hazelnut- allergic patient IgE against 
rCor a 15, the serum of a patient with a known titer of IgE specific to 
α- lactalbumin (as determined by ImmunoCAP) was used as the refer-
ence standard. The reference serum was chosen since it contained 
IgE that was completely unrelated to the allergy that was the subject 
of this study. The reference serum was serially diluted in duplicate 
and added to α- lactalbumin- coated wells. The obtained standard 
curve allowed us to calculate the IgE titers specific to rCor a 15 for 
each patient’s serum.
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TA B L E  1  Clinical characterization of the patient cohort (N=37)
Panel A: first patient recruitment
ID
Patient 
classification Sex Age (y) FHA AD FA PA NA
Hazelnut PbP (ø 




Reduced immunoblotting to 
RAW hazelnut OB
Reduced immunoblotting to 
ROASTED hazelnut OB
Raw Roasted Hazelnut rCor a 1 rCor a 8 rCor a 9 rCor a 14 rBet v 1 14- kDa band 17- kDa band 14- kDa band 17- kDa band
1 HA M 15 Yes Yes Yes No No 6 6 75.80 58.80 1.02 19.20 67.80 55.80 OS, NS, V, ER, AP, LE, H Severe No No Yes Yes
2 HA M 5 Yes Yes No Yes No 13 5 13.70 0.10 0.25 9.80 4.50 <0.10 OAS, LAE Mild Yes Yes Yes Yes
3 HA M 11 Yes No Yes No No 12 6 51.70 72.30 <0.10 4.95 5.43 <0.10 OAS, PI, AP Moderate No Yes No Yes
4 HA F 7 Yes Yes Yes Yes Yes 10 10 28.90 <0.10 <0.10 27.40 39.30 <0.10 V, OAS, PI, ER Moderate No No Yes Yes
5 HA M 8 Yes Yes Yes No Yes 9 8 73.00 64.30 19.20 11.20 26.10 <0.10 V, AS, LE Severe No No Yes Yes
6 HA F 12 Yes Yes Yes Yes Yes 9 8 84.20 <0.10 <0.10 73.40 41.20 n.d. AN Severe No No Yes Yes
7 HA M 7 Yes No Yes Yes Yes 6 4 55.90 <0.10 0.54 39.30 4.16 <0.10 V, AP, ER Moderate Yes No Yes Yes
8 HA F 7 Yes Yes Yes No Yes 5 5 9.55 <0.10 <0.10 19.90 3.94 <0.10 OAS, AP, NS, C, H Severe Yes No Yes Yes
9 HA M 8 Yes Yes Yes Yes Yes 8 5 16.60 11.50 <0.10 6.85 4.76 9.80 OAS, C, ER Moderate Yes Yes Yes Yes
10 HA M 12 Yes No No Yes Yes 10 14 >100 29.10 0.11 >100 >100 36.50 V, AP, U, LE, AS Severe No Yes Yes Yes
11 HA M 11 No No Yes Yes No 3 0 30.70 0.42 36.80 0.69 0.27 4.44 ER Mild No Yes No Yes
12 HA F 16 Yes Yes Yes No Yes 10 8 41.90 <0.10 <0.10 34.70 19.90 <0.10 OAS Mild Yes Yes Yes Yes
13 HA M 10 Yes Yes Yes Yes Yes 10 8 7.45 4.33 <0.10 1.92 1.49 4.40 OAS, PI, ER Mild No Yes Yes Yes
14 HA M 6 Yes Yes No No No 6 7.5 3.75 <0.10 <0.10 <0.10 4.67 <0.10 ER, U, AP, LAE Moderate No Yes Yes Yes
15 HA M 10 Yes Yes No Yes Yes 7 6.5 38.20 59.70 0.75 0.22 <0.10 >100 U, PI Mild No Yes No Yes
16 HA M 10 Yes Yes No Yes Yes 8 4.5 69.00 0.31 >100 29.10 81.50 0.52 U, PI Mild No Yes No Yes
17 HA M 14 Yes Yes Yes Yes Yes 7 8 >100 17.40 2.30 56.90 74.50 57.60 U, PI Mild No Yes Yes Yes
18 HA M 4 Yes Yes No No No 5 15 20.10 <0.10 0.73 8.57 26.30 <0.10 AS, C, R Severe No Yes Yes Yes
19 HA F 13 n.d. Yes Yes Yes Yes 11 7.5 >100 0.12 <0.10 >100 >100 <0.10 U Mild No Yes No Yes
20 HA M 14 Yes Yes Yes Yes Yes 10 7 3.62 <0.10 0.49 9.18 4.94 <0.10 LE, AP Severe No Yes No Yes
21 HA F 9 Yes Yes Yes Yes No 3 6 48.00 2.73 29.80 9.68 34.30 n.d. OAS Mild Yes Yes Yes Yes
22 HA M 2 Yes Yes Yes No Yes 3 0 2.75 0.40 <0.10 n.d. 4.98 <0.10 LAE, U, LE Severe No No No No
23 LIHA M 11 Yes No Yes No Yes 5 5 0.76 <0.10 1.78 0.13 0.47 <0.10 OAS, PI, H Severe No Yes No Yes
24 LIHA M 12 Yes Yes Yes Yes Yes 12 7 1.29 0.55 0.13 <0.10 <0.10 <0.10 LAE, A, U Mild No Yes Yes Yes
25 LIHA M 16 Yes Yes Yes Yes No 7 5 0.71 <0.10 <0.10 0.36 0.76 <0.10 LAE Mild No Yes Yes Yes
26 LIHA M 5 n.d. n.d. Yes No No 5 6 1.59 1.88 <0.10 <0.10 0.70 4.98 LAE Mild No Yes No Yes
27 LIHA F 5 n.d. n.d. No Yes Yes 5 0 0.45 <0.10 <0.10 1.13 0.19 <0.10 OS, U, C Moderate No Yes No Yes
28 HS F 7 Yes Yes Yes No Yes 3 5 7.76 <0.10 6.50 0.32 <0.10 <0.10 None No Yes Yes Yes
29 HS M 6 Yes Yes Yes No No 5 5 24.70 38.10 0.85 <0.10 <0.10 <0.10 None Yes Yes Yes Yes
30 HS F 6 No Yes No Yes Yes 4.5 0 78.00 >100 1.37 1.74 0.69 >100 None No Yes Yes Yes
31 HS M 17 Yes Yes Yes Yes No 10 10 7.42 7.53 <0.10 0.71 0.14 15.80 None No Yes Yes Yes
32 HS F 12 Yes No Yes Yes No 4.5 0 47.40 58.70 <0.10 0.18 <0.10 67.30 None No Yes Yes Yes
33 HS M 11 Yes Yes Yes Yes Yes 3 0 0.65 <0.10 <0.10 <0.10 0.30 <0.10 None No Yes Yes Yes
34 HS M 11 Yes No No Yes Yes 5 0 15.20 <0.10 14.60 <0.10 <0.10 <0.10 None No Yes Yes Yes
35 HS M 9 Yes Yes Yes No Yes 5 4 6.44 <0.10 0.18 1.00 0.91 <0.10 None No Yes Yes Yes
36 HS M 7 Yes No Yes No No 12 9 6.14 <0.10 <0.10 0.65 1.37 <0.10 None No No No Yes
37 HS M 7 Yes Yes No Yes Yes 5 0 54.90 <0.10 <0.10 79.00 6.40 n.d. None No Yes no Yes
Abbreviations: A, angioedema; AD, atopic dermatitis; AN, anaphylaxis; AP, abdominal pains; AS, asthma; C, cough; ER, erythema; F, female; FA, other 
food allergy; FHA, family history of atopy; H, hoarseness; HA, hazelnut- allergic patient; HS, hazelnut- sensitized patient; HY, hypotension; LAE, labial 
edema; LE, laryngeal edema; LIHA, low ImmunoCAP hazelnut- allergic patient; M, male; NA, other nut allergy; NS, nasal symptoms; OAS, oral allergy 
syndrome; OS, ocular symptoms; PA, pollen allergy; PI, pharyngeal itching; R, respiratory problems; U, urticaria; V, vomiting.
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TA B L E  1  Clinical characterization of the patient cohort (N=37)
Panel A: first patient recruitment
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Reduced immunoblotting to 
RAW hazelnut OB
Reduced immunoblotting to 
ROASTED hazelnut OB
Raw Roasted Hazelnut rCor a 1 rCor a 8 rCor a 9 rCor a 14 rBet v 1 14- kDa band 17- kDa band 14- kDa band 17- kDa band
1 HA M 15 Yes Yes Yes No No 6 6 75.80 58.80 1.02 19.20 67.80 55.80 OS, NS, V, ER, AP, LE, H Severe No No Yes Yes
2 HA M 5 Yes Yes No Yes No 13 5 13.70 0.10 0.25 9.80 4.50 <0.10 OAS, LAE Mild Yes Yes Yes Yes
3 HA M 11 Yes No Yes No No 12 6 51.70 72.30 <0.10 4.95 5.43 <0.10 OAS, PI, AP Moderate No Yes No Yes
4 HA F 7 Yes Yes Yes Yes Yes 10 10 28.90 <0.10 <0.10 27.40 39.30 <0.10 V, OAS, PI, ER Moderate No No Yes Yes
5 HA M 8 Yes Yes Yes No Yes 9 8 73.00 64.30 19.20 11.20 26.10 <0.10 V, AS, LE Severe No No Yes Yes
6 HA F 12 Yes Yes Yes Yes Yes 9 8 84.20 <0.10 <0.10 73.40 41.20 n.d. AN Severe No No Yes Yes
7 HA M 7 Yes No Yes Yes Yes 6 4 55.90 <0.10 0.54 39.30 4.16 <0.10 V, AP, ER Moderate Yes No Yes Yes
8 HA F 7 Yes Yes Yes No Yes 5 5 9.55 <0.10 <0.10 19.90 3.94 <0.10 OAS, AP, NS, C, H Severe Yes No Yes Yes
9 HA M 8 Yes Yes Yes Yes Yes 8 5 16.60 11.50 <0.10 6.85 4.76 9.80 OAS, C, ER Moderate Yes Yes Yes Yes
10 HA M 12 Yes No No Yes Yes 10 14 >100 29.10 0.11 >100 >100 36.50 V, AP, U, LE, AS Severe No Yes Yes Yes
11 HA M 11 No No Yes Yes No 3 0 30.70 0.42 36.80 0.69 0.27 4.44 ER Mild No Yes No Yes
12 HA F 16 Yes Yes Yes No Yes 10 8 41.90 <0.10 <0.10 34.70 19.90 <0.10 OAS Mild Yes Yes Yes Yes
13 HA M 10 Yes Yes Yes Yes Yes 10 8 7.45 4.33 <0.10 1.92 1.49 4.40 OAS, PI, ER Mild No Yes Yes Yes
14 HA M 6 Yes Yes No No No 6 7.5 3.75 <0.10 <0.10 <0.10 4.67 <0.10 ER, U, AP, LAE Moderate No Yes Yes Yes
15 HA M 10 Yes Yes No Yes Yes 7 6.5 38.20 59.70 0.75 0.22 <0.10 >100 U, PI Mild No Yes No Yes
16 HA M 10 Yes Yes No Yes Yes 8 4.5 69.00 0.31 >100 29.10 81.50 0.52 U, PI Mild No Yes No Yes
17 HA M 14 Yes Yes Yes Yes Yes 7 8 >100 17.40 2.30 56.90 74.50 57.60 U, PI Mild No Yes Yes Yes
18 HA M 4 Yes Yes No No No 5 15 20.10 <0.10 0.73 8.57 26.30 <0.10 AS, C, R Severe No Yes Yes Yes
19 HA F 13 n.d. Yes Yes Yes Yes 11 7.5 >100 0.12 <0.10 >100 >100 <0.10 U Mild No Yes No Yes
20 HA M 14 Yes Yes Yes Yes Yes 10 7 3.62 <0.10 0.49 9.18 4.94 <0.10 LE, AP Severe No Yes No Yes
21 HA F 9 Yes Yes Yes Yes No 3 6 48.00 2.73 29.80 9.68 34.30 n.d. OAS Mild Yes Yes Yes Yes
22 HA M 2 Yes Yes Yes No Yes 3 0 2.75 0.40 <0.10 n.d. 4.98 <0.10 LAE, U, LE Severe No No No No
23 LIHA M 11 Yes No Yes No Yes 5 5 0.76 <0.10 1.78 0.13 0.47 <0.10 OAS, PI, H Severe No Yes No Yes
24 LIHA M 12 Yes Yes Yes Yes Yes 12 7 1.29 0.55 0.13 <0.10 <0.10 <0.10 LAE, A, U Mild No Yes Yes Yes
25 LIHA M 16 Yes Yes Yes Yes No 7 5 0.71 <0.10 <0.10 0.36 0.76 <0.10 LAE Mild No Yes Yes Yes
26 LIHA M 5 n.d. n.d. Yes No No 5 6 1.59 1.88 <0.10 <0.10 0.70 4.98 LAE Mild No Yes No Yes
27 LIHA F 5 n.d. n.d. No Yes Yes 5 0 0.45 <0.10 <0.10 1.13 0.19 <0.10 OS, U, C Moderate No Yes No Yes
28 HS F 7 Yes Yes Yes No Yes 3 5 7.76 <0.10 6.50 0.32 <0.10 <0.10 None No Yes Yes Yes
29 HS M 6 Yes Yes Yes No No 5 5 24.70 38.10 0.85 <0.10 <0.10 <0.10 None Yes Yes Yes Yes
30 HS F 6 No Yes No Yes Yes 4.5 0 78.00 >100 1.37 1.74 0.69 >100 None No Yes Yes Yes
31 HS M 17 Yes Yes Yes Yes No 10 10 7.42 7.53 <0.10 0.71 0.14 15.80 None No Yes Yes Yes
32 HS F 12 Yes No Yes Yes No 4.5 0 47.40 58.70 <0.10 0.18 <0.10 67.30 None No Yes Yes Yes
33 HS M 11 Yes Yes Yes Yes Yes 3 0 0.65 <0.10 <0.10 <0.10 0.30 <0.10 None No Yes Yes Yes
34 HS M 11 Yes No No Yes Yes 5 0 15.20 <0.10 14.60 <0.10 <0.10 <0.10 None No Yes Yes Yes
35 HS M 9 Yes Yes Yes No Yes 5 4 6.44 <0.10 0.18 1.00 0.91 <0.10 None No Yes Yes Yes
36 HS M 7 Yes No Yes No No 12 9 6.14 <0.10 <0.10 0.65 1.37 <0.10 None No No No Yes
37 HS M 7 Yes Yes No Yes Yes 5 0 54.90 <0.10 <0.10 79.00 6.40 n.d. None No Yes no Yes
Abbreviations: A, angioedema; AD, atopic dermatitis; AN, anaphylaxis; AP, abdominal pains; AS, asthma; C, cough; ER, erythema; F, female; FA, other 
food allergy; FHA, family history of atopy; H, hoarseness; HA, hazelnut- allergic patient; HS, hazelnut- sensitized patient; HY, hypotension; LAE, labial 
edema; LE, laryngeal edema; LIHA, low ImmunoCAP hazelnut- allergic patient; M, male; NA, other nut allergy; NS, nasal symptoms; OAS, oral allergy 
syndrome; OS, ocular symptoms; PA, pollen allergy; PI, pharyngeal itching; R, respiratory problems; U, urticaria; V, vomiting.
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3  |  RESULTS
A flowchart of the experiments and a summary of the main results 
are given in Figure 1.
3.1  |  Study population
The main characteristics of the pediatric subjects included in the study 
are summarized in Table 1. All the patients tested with PbP resulted pos-
itive to raw hazelnuts: 24/27 HA patients and 6/10 HS patients showed 
a wheal diameter ≥ 5 mm. Three HA patients out of 27 and 5/10 HS pa-
tients showed negative PbP results when tested for roasted hazelnuts.
The median scores of the sIgE of rCor a 1, rCor a 8, rCor a 9, and 
rCor a 14 for the HA patients were 0.31 (IQR 0.01– 11.50), 0.11 (IQR 
0.01– 1.02), 9.18 (IQR 0.36– 29.10), and 4.94 (IQR 0.76– 39.30), respec-
tively. The median scores of the sIgE of rCor a 1, rCor a 8, rCor a 9, and 
rCor a 14 for the HS patients were 0.01 (IQR 0.01– 38.10), 0.10 (IQR 
0.01– 1.37), 0.49 (IQR 0.01– 1.00), and 0.22 (IQR 0.01– 0.91), respec-
tively. The HA and HS patients differed significantly as far as the rCor 
a 9 and rCor a 14 values are concerned (pCora9 = 0.004, pCora14 = 0.002), 
while Cor a 1 and Cor a 8 did not discriminate the HA from the HS pa-
tients (pCora1 = 0.75, pCora8=0.98). Furthermore, the rCor a 9 and rCor 
a 14 values were directly correlated (r2 = 0.67; p < .001). Seventeen 
patients (12/27 HA patients and 5/10 HS patients) also suffered from 
a pollen allergy (PA). Finally, 17/27 HA patients and 6/10 HS patients 
were allergic to other tree nuts (NA). It was not possible to establish a 
correlation between the severity grading and oleosin immunorecog-
nition because of the limited number of LIHA patients.
3.2  |  Discovery of two new hazelnut oleosins
The OB- associated proteins were separated (Figures 2 and 3) and 
identified (Table 2, Table S1, and Table S2), and two new oleosin- like 
proteins were found (Figure S1). Their sequences were submitted to 
F I G U R E  1  Workflow of the experiments
• Immunocap for hazelnut extract, Cor a 1, 8, 9, 14
• OFC with roasted hazelnut
• PbP with raw and roasted hazelnut
symptom grading: classification as HA, LIHA or HS patients
Cor a 15 DISCOVERY
CLASSIFICATION OF THE PATIENTS
Cor a 15 IMMUNOREACTIVITY IN ALLERGIC PATIENTS 
1-DE Immunoblotting with a single patient’s
serum
5 HA patients classified as LIHA (Low Immunocap Hazelnut Allergic) patients
recognized by 88% of the allergic patientsband 2A contained 100% Cor a 15
89.5% Cor a 15
10.5% Cor a 12
RAW:
ROASTED: recognized by 96% of the allergic patients
all the allergic patients resulted positive to raw hazelnut PbP
band 2B contained
2-DE Immunoblotting with a pool of 
LIHA patients’ sera
• LIHA patients only immunorecognized oleosins containing spots (Panel C and D)
• LIHA patients did not recognize Cor a 9 and 11 containing spots (Panel D)
• The spots containing Cor a 15 were markedly more immunoreactive than the spots containing Cor a 
12 and Cor a 13 (Panel C, spot 1A2DE and 2A2DE)
OLEOSIN IMMUNOREACTIVITY IN THE LIHA PATIENTS
PROOF OF Cor a 15 IMMUNOREACTIVITY BY MEANS OF INHIBITION TESTING AND QUANTIFICATION OF  rCor a 15 IgEs
complete inhibition of Cor a 15 containing bands - recognition by both the HA and LIHA patient poolsINHIBITION TESTING with
rCor a 15 (Fig. 4)
ELISA TEST with rCor a 15
(Fig. 5)
semi-quantification of Cor a 15 IgE for the HA, LIHA and HS patients
Recruitment: 27 HA (Hazelnut Allergic) and 10 HS (Hazelnut Sensitized but tolerant) patients (Tab. 1)
Oleosin extraction from raw and roasted hazelnuts
Separation by means of  LDS-PAGE (Fig. 2)
Identification by means of MALDI-TOF/TOF and LC-MS
Discovery of a new oleosin sequence - MK737923 (termed Cor a 15 by WHO/IUIS Allergen Nomenclature Subcommittee) (Tab. 2)
Resolved raw hazelnut oleosins Unresolved roasted hazelnuts
(comigration of oleosins with Cor a 9 and 11)
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GenBank under accession numbers MK737923 and MK737924. The 
MK737923 sequence showed 56% similarity with Cor a 12 and 41% 
with Cor a 13. The MK737924 sequence showed 63% similarity with 
Cor a 12 and 76% with Cor a 13 (Figure S2).
3.3  |  IgE reactivity to hazelnut OB- associated 
proteins and discovery of Cor a 15
We hypothesized that other allergens, not included in the ImmunoCAP 
assay, could account for the positivity of the LIHA patients to OFC. 
We thus performed immunoblotting to evaluate the immunoreactiv-
ity of the single patients to the OB- associated proteins. Two oleosin- 
containing bands were found at 14 and 17 kDa (Figure 2).
One hundred percent of the allergic patients recognized at least 
one oleosin- containing band (Table 1). Thirty- three percent recog-
nized the 14- kDa band, containing both Cor a 12 and Cor a 13 (band 
1A in Figure 2, Table 2). The 17- kDa band, which exclusively con-
tains the MK737923 oleosin (band 2A in Figure 2 and Table 2), was 
the most recognized one and was immunoreactive for 88% of the 
allergic patients. The MK737923 oleosin was therefore submitted 
as an allergen candidate to the WHO/IUIS Allergen Nomenclature 
Subcommittee, who approved it as a new hazelnut allergen and 
termed it Cor a 15. The three hazelnut oleosins were also immuno-
recognized by the HS patients, with a similar frequency to that of the 
allergic patients (Table 1 and Figure 2).
In order to verify that the LIHA patients did not recognize 
any other water- soluble allergens than those found negative by 
ImmunoCAP, a total hazelnut water- soluble protein extract was 
tested by immunoblotting against the pooled sera of the LIHA pa-
tients (nos. 23, 24, and 25) and against the pooled sera of the HA 
patients (nos. 1 to 14). The IgEs of the LIHA patients did not bind 
with any protein band, while several protein bands were recognized 
by the HA pool (Figure S3).
3.4  |  Effect of roasting on the hazelnut 
oleosin profile
We further assessed whether the hazelnut OB protein profile 
was affected by processing, since hazelnuts are usually consumed 
roasted. In addition to the 14- kDa and 17- kDa bands, higher MW 
bands appeared (Figure 2, panel B). The 14- kDa band, containing a 
mixture of Cor a 12 and Cor a 13 (band 1B in Figure 2 and Table 2), 
F I G U R E  2  For each panel: first lane, stained LDS- PAGE of raw (A) and roasted (B) OB- associated protein extracts; lanes 1 to 37: 
immunoblotting with individual patient’s serum. C, a pool of five sera of non- nut- allergic (NNA) pediatric subjects was used as a control. CII, 
secondary antibody control. MW, molecular weight; HA, hazelnut- allergic patients; LIHA, low ImmunoCAP hazelnut- allergic patients; HS, 
hazelnut- sensitized patients
100% Cor a 15
89.5% Cor a 15
10.5% Cor a 12
64.4% Cor a 13
35.6% Cor a 12
78.4% Cor a 13
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was recognized by 62% of the allergic patients (Table 1). The 17- kDa 
band, containing Cor a 15 with traces of Cor a 12 (band 2B in Figure 2 
and Table 2), was again the most recognized band (96% of the aller-
gic children) (Table 1). The bands around 20– 40 kDa, generated by 
roasting, were recognized by almost all the patients. In addition to 
oleosins, these bands also contained Cor a 9 and/or Cor a 11 soluble 
hazelnut allergens (bands 3B to 8B in Figure 2, Table 2). To discrimi-
nate whether the LIHA patients’ sera immunoreacted to Cor a 9 and 
Cor a 11 or against oleosins, a 2DE separation of the OB- associated 
proteins was performed, exploiting the different isoelectric points of 
these allergens (Figure 3, panels A and B). Most of the spots in the 
alkaline zone (right part) of the 2DE map were identified as oleosins, 
or as the basic subunit of Cor a 9, while those in the acidic zone were 
found to contain acidic subunits of Cor a 9 and Cor a 11 (Table 2).
In spite of the different 2DE protein profiles of the raw and 
roasted OB proteins (Figure 3, Panel A and B), the immunoreactivity 
profiles were very similar (Figure 3, Panels C and D) and exclusively 
localized in the alkaline region.
3.5  |  Hazelnut oleosins are major allergens for 
LIHA patients and Cor a 15 is the most frequently 
recognized oleosin
Most reactive spots on 2DE separation of raw and roasted ex-
tracts contained co- migrating oleosins exclusively: Cor a 12, Cor 
a 13, and Cor a 15 (Figure 3, Table 2). Interestingly, the 1A2DE and 
2A2DE spots, which showed a similar densitometric intensity in the 
2DE gel, resulted in a highly different immunoreactivity. Spot 2A2DE, 
which contained 96.5% of Cor a 15, was much more immunoreactive 
than the 1A2DE spot, which exclusively contained Cor a 12 and 13 
(Figure 3, Panels A and C, and Table 2).
In order to verify whether Cor a 15 was the most frequently rec-
ognized oleosin, full- length Cor a 15 and its C- term fragment (from 
aa 102 to aa 168) were expressed and purified (Figure 4, panels A 
and C). The C- terminal fragment was expressed because it contains 
a similar peptide (11 aa out of 14 aa) to the most immunoreactive IgE 
epitope in Ara h 154 (Figure S4). The addition of full- length rCor a 15 
to both the LIHA and HA pooled patients’ sera completely inhibited 
the recognition of the 17- kDa band exclusively containing Cor a 15 
(Figure 4, panel B). The same amount of rCor a 15 C- terminal did not 
result in the complete inhibition of the immunoreactivity of the sera 
(Figure 4, panel D). Moreover, the reverse was also true: the hazelnut 
oleosins present in the OB extract were able to inhibit the Cor a 15 
immunorecognition by the patients’ sera (Figure 4, panel E).
3.6  |  All the patients showed specific IgEs toward 
Cor a 15
In order to obtain a semi- quantification of the patients’ IgEs that 
were specific to Cor a 15 in the different subgroups of patients 
F I G U R E  3  2- DE and immunoblotting of the OB- associated protein extracts. 2- DE of raw (A) and roasted (B) hazelnut OB protein extracts. 
Immunoblotting of raw (C) and roasted (D) hazelnut OB protein extracts with the pool of sera of the LIHA patients (nos. 23, 24, and 25). 
Immunoblotting of raw (E) and roasted (F) hazelnut OB protein extracts with a pool of five sera of non- nut allergic (NNA) pediatric subjects. 
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65.8% Cor a 15
18.8% Cor a 13
15.4% Cor a 12 62.2% Cor a 15
16.2% Cor a 12
7.90% Cor a 13
45.3% Cor a 12
39.8% Cor a 15
14.9% Cor a 13
74.8% Cor a 15
16.4% Cor a 13
8.80% Cor a 12
72.6% Cor a 12
22.2% Cor a 13
5.10% Cor a 15
96.5% Cor a 15
3.50% Cor a 12
64.1% Cor a 12
35.9% Cor a 13
83.3% Cor a 15
16.7% Cor a 12
80.6% Cor a 15
19.4% Cor a 13
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TA B L E  2  1- DE and 2- DE protein identification










1- DE protein identification
Raw hazelnut
1A AAO65960 Cor a 13 14,000/14,723 776 7 36.6 78.4
AAO67349 Cor a 12 14,000/16,745 455 4 26.9 21.6
2A MK737923 Cor a 15 17,000/17,695 1045 7 45.9 100
Roasted hazelnut
1B AAO65960 Cor a 13 14,000/14,723 1231 6 38.9 64.4
AAO67349 Cor a 12 14,000/16,745 624 6 34.8 35.6
2B MK737923 Cor a 15 17,000/17,695 1080 8 45.9 89.5
AAO67349 Cor a 12 17,000/16,745 140 3 21.7 10.5
3B AHA36627 Cor a 9 22,000/59,200 1853 14 31.2 69.5
AAO65960 Cor a 13 22,000/14,723 203 4 26.9 30.6
4B AHA36627 Cor a 9 23,000/59,200 2268 17 28.4 100
5B AAO65960 Cor a 13 27,000/14,723 456 4 29.1 47
AAO67349 Cor a 12 27,000/16,745 378 4 26.9 38.3
AHA36627 Cor a 9 27,000/59,200 433 7 16.2 14.7
6B MK737923 Cor a 15 29,000/17,695 293 5 36.6 40.6
AAO65960 Cor a 13 29,000/14,723 401 4 29.1 27.2
AAO67349 Cor a 12 29,000/16,745 410 4 26.9 22.2
AHA36627 Cor a 9 29,000/59,200 539 8 18.6 10.1
7B MK737923 Cor a 15 34,000/17,695 78 4 36.6 53.6
AHA36627 Cor a 9 34,000/59,200 181 3 21.7 46.4
8B AHA36627 Cor a 9 38,000/59,200 524 8 19.9 68.8
AAO67349 Cor a 12 38,000/16,745 178 4 26.9 31.2










2- DE protein identification
Raw hazelnut
1A2DE AAO67349 Cor a 12 14,000/16,745- 10.00/10.54 4430 8 38.8 64.1
AAO65960 Cor a 13 14,000/14,723- 10.00/9.98 3846 8 41.1 35.9
2A2DE MK737923 Cor a 15 17,000/17,695- 10.00/9.56 3709 13 55.8 96.5
AAO67349 Cor a 12 17,000/16,745- 10.00/10.54 666 5 28.9 3.5
3A2DE MK737923 Cor a 15 29,000/17,695- 10.00/9.56 889 8 49.6 62.2
AAO67349 Cor a 12 29,000/16,745- 10.00/9.98 404 4 26.9 16.2
AAO65960 Cor a 13 29,000/14,723- 10.00/10.54 563 4 29.1 13.7
MK737924 Oleosin 29,000/15,790- 10.00/9.43 93 3 18.7 7.9
4A2DE MK737923 Cor a 15 34,000/17,695- 10.00/9.56 1298 8 45.9 65.8
AAO65960 Cor a 13 34,000/14,723- 10.00/9.98 524 4 29.1 18.8






10  |    NEBBIA Et Al.










1B2DE AAO67349 Cor a 12 14,000/16,745- 10.00/10.54 1679 7 35.5 81
AAO65960 Cor a 13 14,000/14,723- 10.00/9.98 1051 5 31.4 19.0
2B2DE AAO67349 Cor a 12 15,000/16,745- 10.00/10.54 2155 7 39.4 72.6
AAO65960 Cor a 13 15,000/14,723- 10.00/9.98 1001 5 31.4 22.2
MK737923 Cor a 15 15,000/17,695- 10.00/9.56 134 3 24.8 5.1
3B2DE AAO67349 Cor a 12 17,000/16,745- 10.00/9.56 920 6 34.2 45.3
MK737923 Cor a 15 17,000/17,695- 10.00/9.98 1054 7 45.3 39.8
AAO65960 Cor a 13 17,000/14,723- 10.00/10.54 962 4 29.1 14.9
4B2DE AHA36627 Cor a 9 22,000/59,200- 10.50/8.93 1406 13 27.8 100
5B2DE Not identified
6B2DE AHA36627 Cor a 9 23,000/59,200- 10.00/8.93 4799 14 30.2 57.1
MK737923 Cor a 15 23,000/17,695- 10.00/9.10 132 5 36.6 27.0
AAO65960 Cor a 13 23,000/14,723- 10.00/9.56 273 3 34.3 15.9
7B2DE AHA36627 Cor a 9 23,000/59,200- 9.00/8.93 6112 14 32.3 81.1
MK737923 Cor a 15 23,000/17,695- 9.00/9.56 124 4 36.6 18.9
8B2DE AHA36627 Cor a 9 23,000/59,200- 8.50/8.93 3519 14 29 100
9B2DE AHA36627 Cor a 9 22,000/59,200- 10.00/9.56 3333 18 29.4 84.5
MK737923 Cor a 15 22,000/17,695- 10.00/10.54 56 3 30.4 15.5
10B2DE AHA36627 Cor a 9 22,000/59,200- 9.00/8.93 2197 13 27.4 75.1





15B2DE AAL86739 Cor a 11 27,000/51,110- 5.00/6.12 473 8 23.2 100
16B2DE AAL86739 Cor a 11 24,000/51,110- 5.00/6.15 536 8 22.4 75.2
AHA36627 Cor a 9 24,000/59,200- 5.00/6.12 616 5 15.2 24.8
17B2DE AHA36627 Cor a 9 30,000/59,200- 5.00/6.15 296 5 14.4 60,6
AAL86739 Cor a 11 30,000/51,110- 5.00/6.12 145 3 9.2 39,4
18B2DE AHA36627 Cor a 9 38,000/59,200- 5.00/6.15 189 5 15.7 51.4
AAL86739 Cora 11 38,000/51,110- 5.00/6.12 112 5 9.4 48.6
19B2DE AHA36627 Cor a 9 38,000/59,200- 5.70/6.15 1562 16 45.1 100
20B2DE AHA36627 Cor a 9 38,000/59,200- 6.00/6.46 1702 17 40.1 90.8
AAL86739 Cor a 11 38,000/51,110- 6.00/6.12 122 5 13.2 9.2
21B2DE AAL86739 Cor a 11 45,000/51,110- 6.20/6.12 4659 24 55.3 91.4
AHA36627 Cor a 9 45,000/59,200- 6.20/5.69 985 15 39 8.6
22B2DE MK737923 Cor a 15 17,000/17,695- 8.00/9.56 803 6 45.3 80.6
AAO65960 Cor a 13 17,000/14,723- 8.00/9.98 174 3 28.4 19.4
23B2DE MK737923 Cor a 15 17,000/17,695- 6.70/9.56 17741 7 44.6 83.3
AAO67349 Cor a 12 17,000/16,745- 6.70/10.54 16745 3 21.7 16.7
24B2DE MK737923 Cor a 15 36,000/17,695- 10.00/9.56 1055 8 45.9 74.8
AAO65960 Cor a 13 36,000/14,723- 10.00/9.98 517 4 29.1 16.4
AAO67349 Cor a 12 36,000/16,745- 10.00/10.54 350 3 28.2 8.8
TA B L E  2  (Continued)
(Continues)
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(HA, LIHA, and HS) and in the negative controls (NNA and NFA), 
the patients’ sera were tested by means of an in- house direct 
ELISA test. The patients’ sera all showed specific IgEs for rCor 
a 15 (Figure 5); however, the ELISA test did not differentiate be-
tween the HA, LIHA, and HS patients on the basis of Cor a 15 
immunorecognition, as already demonstrated by the immunoblot-
ting experiments. An aspecific reaction was found in 3/18 of the 
control sera.
4  |  DISCUSSION
With the aim of conducting an immune- allergological characterization 
of hazelnut oleosins in pediatric patients, we performed the isolation 
and identification of hazelnut OB- associated proteins. We were able 
to separate oleosins from soluble allergens and to identify, for the first 
time, a new allergen belonging to the oleosin family, termed Cor a 15 
by WHO- IUIS. We then demonstrated the immunogenic power of 
F I G U R E  4  Immunoblotting inhibition assay. Panels A and C: LDS- PAGE of full- length rCor a 15 (rCor a 15) and rCor a 15 C- terminal (rC- 
term), respectively. Immunoblotting with pooled sera of the LIHA patients (25, 26 and 27) and HA patients (2, 10, and 13). CII: secondary 
antibody control; MW: molecular weight. Panels B and D: LDS- PAGE of raw hazelnut OB protein extracts (raw OB). Immunoblotting with the 
pooled sera of the LIHA patients (25, 26, and 27) and HA patients (2, 10, and 13), without (Tq) and with the addition of 0.2 and 2 µg of rCor 
a 15 and rCor a 15 C- terminal to the patients’ sera, respectively. Panel E: Immunoblotting with the sera of 10 patients (nos. 4, 5, 9, 16, 17, 18, 
19, 27, 36, and 37) without (Tq) and with the addition of 3 and 6 µg of raw OB protein extract to the patients’ sera. C1: pool of five sera of 
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the newly reported Cor a 15 oleosin for most of our hazelnut- allergic 
pediatric patients. In addition, we succeeded in unambiguously as-
cribing the immunoreactivity of LIHA patients (characterized by low 
ImmunoCAP assay IgEs values and positive OFC and PbP) only to ole-
osins, thereby excluding the contribution of other allergens.
Regarding the IgE levels, the Cor a 9 and Cor a 14 IgE levels were 
clearly associated with the elicitation of the allergic reaction, accord-
ing to Datema et al.,21 and were useful to discriminate between the 
hazelnut- allergic and hazelnut- sensitized but tolerant patient groups. 
This was not found for the Cor a 1 and Cor a 8 IgE levels, for which a 
moderate diagnostic predictive value has been demonstrated.22 The 
IgE levels of the newly discovered Cor a 15 seemed to have a similar 
behavior, as they were unable to discriminate between allergic and 
sensitized patients.
The evaluation of oleosin immunoreactivity for hazelnut- allergic 
patients was assessed by 1D and 2D immunoblotting, coupled with 
protein identification by means of mass spectrometry. The results 
indicated that all the HA patients immunorecognized at least one 
oleosin, although it was not possible to assess the role of the oleo-
sins in eliciting the allergic reaction, as they were co- sensitized to 
genuine hazelnut allergens. On the contrary, we found that a subset 
of LIHA patients exclusively immunorecognized oleosins and, among 
them, mainly Cor a 15. Cor a 15 appeared to be the best candidate 
for the allergic reaction in this subgroup of patients. This evidence 
highlights the relevance of dosing IgEs against Cor a 15 in hazelnut 
allergy diagnosis. We also observed IgE reactivity to hazelnut oleo-
sins in the HS patients, which could be ascribed to a cross- reactivity 
with other oleosins, at least for those patients with a confirmed al-
lergy to other nuts.23
Cor a 15, which we exclusively identified in the 17- kDa band, was 
the most immunorecognized oleosin (88% of the allergic patients). 
This result was different from the results of Zuidmeer- Jongejan, who 
detected both Cor a 12 and Cor a 13 in a band at the same MW.7 This 
is probably due to the lack of Cor a 15 gene sequence in the database 
at the time of the protein identification. We also identified Cor a 12 
and 13 in a band at 14 KDa, with a recognition frequency of 33%, 
similar to what was reported in the EuroPrevall project for Cor a 12 
in children (34%).2
As already demonstrated by Schwager et al.4 for Ara h 15, we hy-
pothesized that the epitope responsible the most for Cor a 15 immu-
norecognition is located at the C- terminal, since both the full- length 
rCor a 15 and rCor a 15 C- terminal were able to inhibit IgEs against 
the 17- kDa band containing only Cor a 15.
Our findings also show a resistance of oleosins to high tempera-
tures, which resulted in an apparent enhancement of oleosin immu-
noreactivity after roasting, with a more evident effect on Cor a 12 
and Cor a 13.15 The immunorecognition of roasted Cor a 12 and Cor 
a 13 exceeded 60% for the allergic patients, while Cor a 15 reached 
96%. Similarly, Schwager et al.4 demonstrated an increase in oleo-
sin immunoreactivity after roasting in- shell peanuts. Glycation after 
roasting may play a role in increasing the affinity and/or the accessi-
bility of oleosins to IgEs.24
In conclusion, we have discovered a new hazelnut oleosin aller-
gen, Cor a 15, which resulted to play a role in eliciting an allergic 
reaction in a subgroup of our pediatric patients that exclusively im-
munorecognized oleosins, thus confirming the relevance of including 
lipophilic allergens in the protein extracts used for diagnostic tests.
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